Biogen Inc. (BIIB)
After hours:
| Previous Close | 194.11 |
| Open | 193.34 |
| Bid | 192.84 x 300 |
| Ask | 193.08 x 300 |
| Day's Range | 192.75 - 195.86 |
| 52 Week Range | 189.44 - 319.76 |
| Volume | |
| Avg. Volume | 1,192,172 |
| Market Cap | 28.081B |
| Beta (5Y Monthly) | -0.01 |
| PE Ratio (TTM) | 24.27 |
| EPS (TTM) | 7.96 |
| Earnings Date | Apr 24, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 297.80 |
Insider MonkeyShould You Be Confident in Biogen (BIIB)?
Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter 2024 investor letter. A copy of the same can be downloaded here. During the quarter the strategy returned 11.8% net of fees compared to the S&P 500’s 10.6% return. The outperformance of the portfolio can be attributed to selection and […]
ZacksWhat's in Store for Biogen (BIIB) This Earnings Season?
Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.
ZacksGear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
